- What Does CRF Stand For in Clinical Research?
- Paper CRF vs. Electronic CRF (eCRF)
- Regulatory Standards That Govern CRF Design in Device Trials
- CRF Design: What Gets It Right and What Gets It Wrong
- CRFs in First-in-Human Device Trials: What Changes at This Stage
- Automated CRF Filling: Where NLP and LLMs Are Heading
- How CRF Quality Affects the Submission-Ready Evidence Package
- Frequently Asked Questions
- The CRF Is a Submission Instrument, Not a Paperwork Exercise
Category: General
A case report form sits at the center of every clinical trial, yet the CRF medical abbreviation still trips up founders and clinical operations leads who are new to regulated research. If you are preparing for a first-in-human (FIH) study or structuring data for an IDE submission, understanding what a CRF is, how it is designed, and what standards govern it is not optional. It is the foundation on which your entire evidence package rests.
This article explains the CRF from first principles, covers the distinction between paper and electronic formats, walks through the regulatory standards that apply specifically to medical device trials, and addresses the design decisions that most affect data quality at submission.
What Does CRF Stand For in Clinical Research?
CRF stands for Case Report Form. It is a structured data collection instrument used in clinical trials to record every observation, measurement, and event specified in the study protocol for each individual participant. The form captures data at defined time points — from screening through the final follow-up visit — and serves as the primary record that flows into the clinical database.
The CRF is not the same as a source document. Source documents are the original records created at the point of care: hospital charts, lab printouts, imaging reports. The CRF is a transcription of the relevant data points from those source documents into a standardized format that can be verified, audited, and submitted to a regulatory authority.
That distinction matters for device trials in particular. Under FDA 21 CFR 812 and ISO 14155, every CRF entry must be traceable back to a source document. If a field in the CRF cannot be reconciled with a source record, that data point is at risk during an FDA inspection.
Paper CRF vs. Electronic CRF (eCRF)
Early clinical trials used paper CRFs: multi-part carbon forms completed by hand at the investigator site and couriered to the sponsor for manual entry. The format was slow, error-prone, and difficult to audit.
Electronic case report forms — eCRFs — are now standard practice. Hosted within an Electronic Data Capture (EDC) system, they allow real-time data entry, automated range checks, and immediate query generation when an entry falls outside protocol-specified parameters. For a device startup running a lean FIH study, the eCRF also eliminates the transcription layer, cutting one common source of data errors before they reach the database.
The regulatory expectations are the same regardless of format. Whether a CRF is paper or electronic, it must satisfy the ALCOA+ attributes: data must be Attributable, Legible, Contemporaneous, Original, and Accurate — and in the extended ALCOA+ framework, also Complete, Consistent, Enduring, and Available. An eCRF system that enforces mandatory fields, timestamps entries, and logs every change with an audit trail makes ALCOA+ compliance structurally easier to demonstrate.
Regulatory Standards That Govern CRF Design in Device Trials
ICH E6 and ISO 14155
For drug trials, ICH E6(R2) and its successor ICH E6(R3) set the GCP framework governing CRF requirements. For medical device trials, ISO 14155 is the governing standard. It defines the clinical investigation requirements for medical devices intended for human subjects and specifies that the CRF must be designed to collect all protocol-required data in a manner that supports data integrity and regulatory review.
When a device trial is run outside the United States, FDA 21 CFR 812.28 provides the framework for how foreign clinical data can be used in a U.S. IDE or IND submission. Data collected under ISO 14155 and structured per 21 CFR 812.28 is eligible for use in those submissions. That eligibility depends, in part, on CRF design: if the form does not capture the fields the FDA expects to see in a submission-ready evidence package, the data cannot fill the regulatory gap — regardless of how well the study was executed.
CDASH and Standardization
The Clinical Data Acquisition Standards Harmonization (CDASH) model, maintained by CDISC, provides a standard set of data collection fields and their definitions. CDASH-aligned CRFs make it significantly easier to convert collected data into CDISC SDTM format for regulatory submission. For device startups preparing an IDE package, building CDASH alignment into the CRF at the protocol development stage avoids a costly, time-consuming data mapping exercise later.
CRF Design: What Gets It Right and What Gets It Wrong
Field Design and Data Integrity
Most data quality problems originate at the field design level. Ambiguous labels, free-text fields where coded responses should be used, and missing visit windows all generate queries that slow database lock and delay submission.
A 2026 guide published by ccrps.org identifies 30 high-impact CRF fields that must be captured cleanly to ensure trial data integrity. The implication for device sponsors is direct: field-level decisions made during protocol development determine whether the database locks on schedule or whether the trial team spends months resolving queries before submission.
For device trials specifically, the CRF must include fields that drug trial templates simply do not cover: device identification (lot number, serial number, version), implant and explant dates, device malfunctions, and any unanticipated adverse device effects (UADEs). These fields are required under ISO 14155 and must be present in the CRF design before the first patient is enrolled.
Lean CRF Design Without Losing Required Data
There is a real tension in CRF design between capturing everything the protocol requires and keeping the form manageable for investigators at busy clinical sites. Overloaded CRFs increase site burden, slow data entry, and generate more queries — not fewer.
A 2019 report from hfcollaboratory.com documented this directly in the context of heart failure device trials: a lean case report form reduced the number of distinct data items from 176 to 75 baseline items without compromising the data required for the primary endpoint. The lesson is not that shorter is always better. Every field in the CRF should be justified by the protocol's endpoints and the regulatory submission requirements — nothing more, nothing less.
Screening and Randomization Fields
The fields governing eligibility are among the most consequential in the entire CRF. Incomplete or inconsistently captured inclusion and exclusion criteria produce protocol deviation findings that can affect the integrity of the intent-to-treat population. For a small FIH study where every patient in the safety cohort counts, a protocol deviation at screening is not a minor administrative issue.
CRFs in First-in-Human Device Trials: What Changes at This Stage
FIH studies are not Phase III trials with hundreds of patients and a powered primary endpoint. They are typically small safety and feasibility studies designed to demonstrate that a device can be used in humans without unacceptable risk and to generate preliminary performance data. The CRF reflects that purpose.
The form must capture safety data comprehensively: adverse events, serious adverse events, device malfunctions, and UADEs at every visit. It must also capture the performance endpoints specified in the protocol — in a device trial, those often include procedural success criteria, imaging or functional assessments, and patient-reported outcomes. Because the FIH dataset will anchor the IDE or IND submission, the CRF must be designed with the submission endpoint in mind from the start, not retrofitted after data collection is complete.
This is where CRO experience with the regulatory submission pathway matters. A CRO that has structured CRFs for IDE submissions knows which fields the FDA will scrutinize, which data points support the Pre-Sub strategy, and how CRF design connects to the statistical analysis plan. A generic template borrowed from a drug trial or an earlier-generation device study is unlikely to capture the device-specific fields a submission reviewer will look for.
Automated CRF Filling: Where NLP and LLMs Are Heading
One area of active development in clinical data management is the automated population of CRF fields from unstructured clinical notes using natural language processing (NLP) and large language models (LLMs). The appeal is straightforward: if a model can read a clinical note and extract the relevant data points directly into the CRF, it reduces transcription burden and the queries that come from manual entry errors.
Research published in 2026 by ACL Anthology on a two-stage LLM pipeline for CRF filling reported a macro F1 score of 0.56 for both English and Italian in the CRF Filling Shared Task 2026. A separate 2026 dataset described by lrec-conf.org for dyspnea assessment included 134 medical items with predefined value sets, illustrating the complexity of mapping free-text clinical language to structured CRF fields at scale.
These results are promising but not yet at the accuracy threshold required for unreviewed regulatory submission. For device sponsors in 2026, automated CRF filling tools are worth monitoring — particularly for high-volume data entry tasks — but human verification remains a regulatory requirement for data submitted to the FDA.
How CRF Quality Affects the Submission-Ready Evidence Package
A well-designed CRF is not just a data collection tool. It is the instrument that converts clinical observations into a regulatory submission. When the CRF is built around the protocol's endpoints, aligned to CDASH, and structured to capture the device-specific fields required under ISO 14155, the path from database lock to submission-ready evidence package is direct.
When it is not, the path is anything but. Queries accumulate, database lock is delayed, data mapping to CDISC formats requires manual intervention, and the submission timeline extends. For a startup with a 12-month financial runway and an investor milestone tied to IDE submission, a CRF design problem discovered at database lock is a serious operational risk.
This is one reason bioaccess® builds CRF design into the protocol development workstream of the FIH-12™ program, rather than treating it as a downstream data management task. The FIH-12™ program covers all nine workstreams from FDA strategy alignment through delivery of the submission-ready evidence package, with CRF design anchored to the sponsor's specific IDE or IND pathway from day one.
Case studies published at bioaccessla.com/case-studies/cook-group and bioaccessla.com/case-studies/celonova-biosciences illustrate how CRF architecture integrates with multi-site FIH execution under INVIMA and other Latin American regulatory frameworks. The ClarVista Medical case study shows how a well-structured evidence package — built from a CRF designed for submission — supported a clinical program that ultimately led to acquisition by Alcon.
If you are at the stage of designing your FIH protocol and want to understand how CRF design connects to your FDA Pre-Sub strategy and submission timeline, the bioaccess® FIH-12™ program overview is the starting point.
Frequently Asked Questions
What does CRF stand for in medical and clinical trial contexts?
CRF stands for Case Report Form. It is the structured instrument used in clinical trials to record protocol-specified data for each participant, from screening through final follow-up. Every data point submitted to a regulatory authority in a clinical evidence package originates from the CRF.
How is a CRF different from a source document?
A source document is the original record created at the point of care — a hospital chart, lab report, or imaging file. The CRF is a transcription of the relevant data points from those source documents into a standardized format. Under FDA 21 CFR 812 and ISO 14155, every CRF entry must be traceable back to a source document.
What regulatory standards govern CRF design in medical device trials?
ISO 14155 is the primary standard for medical device clinical investigations. ICH E6(R2) and ICH E6(R3) govern GCP requirements more broadly. When foreign clinical data is intended for use in a U.S. IDE or IND submission, FDA 21 CFR 812.28 applies. CDASH alignment is the standard approach for structuring CRF fields to support CDISC SDTM conversion at submission.
What are ALCOA+ attributes and why do they matter for CRF data?
ALCOA+ is the data integrity framework applied to clinical trial records. It requires that data be Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available. An eCRF system with mandatory fields, audit trails, and timestamped entries makes ALCOA+ compliance structurally easier to demonstrate during an FDA inspection.
What device-specific fields must a CRF include that drug trial templates typically omit?
Device CRFs must capture device identification data (lot number, serial number, software version), implant and explant dates, device malfunctions, and unanticipated adverse device effects (UADEs). These fields are required under ISO 14155 and must be present before the first patient is enrolled.
Can CRFs be automatically filled using AI or large language models?
Research published in 2026 by ACL Anthology on an LLM pipeline for CRF filling reported a macro F1 score of 0.56, indicating meaningful but imperfect performance. Automated tools can reduce transcription burden for high-volume tasks, but human verification of CRF entries remains a regulatory requirement for data submitted to the FDA.
How does CRF design affect the timeline for IDE submission?
A CRF that is not aligned to the protocol's endpoints, not built to CDASH, or missing device-specific required fields will generate queries at database lock that delay submission. For a startup with a milestone tied to IDE filing, a CRF design problem discovered late in the trial is both an operational and financial risk. Building CRF design into protocol development — rather than treating it as a downstream task — is how that outcome is avoided.
The CRF Is a Submission Instrument, Not a Paperwork Exercise
Every field in your CRF is either supporting your IDE submission or creating a problem for it. The design decisions made during protocol development determine which outcome you get. For device startups running FIH studies in Latin America under ISO 14155 and targeting FDA submission under 21 CFR 812.28, the CRF is the connective tissue between clinical execution and regulatory approval.
Treat it as a submission instrument from the first draft. Build it around your endpoints, align it to CDASH, capture every device-specific field ISO 14155 requires, and verify that every entry can be traced to a source document. That discipline at the design stage is what makes the path from database lock to submission-ready evidence package a straight line.
Learn more at bioaccessla.com.
Leave a Reply